Negative predictive value of positron emission tomography/computed tomography in patients with a clinical suspicion of pancreatic cancer

Pancreas

Volumn 40, Issue 5, 2011, Pages 653-656

  Lin, James L ^a,c   Barthel, James S ^a   Keshishian, Jonathan ^a   Eikman, Edward A ^b   Klapman, Jason B ^a  

^a Section Endoscopic Oncology   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^c NONE   (United States)

Author keywords

endoscopic ultrasound; pancreatic cancer; pancreatic cyst; pancreatic mass; PET; PET CT

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ASPIRATION BIOPSY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CYST; CYTOLOGY; DIAGNOSTIC TEST ACCURACY STUDY; DIGESTIVE SYSTEM INJURY; ENDOSCOPIC ECHOGRAPHY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PANCREAS CANCER; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVIEW; SOLID TUMOR;

ADULT; AGED; AGED, 80 AND OVER; BIOPSY; BIOPSY, FINE-NEEDLE; COHORT STUDIES; FALSE NEGATIVE REACTIONS; FEMALE; FLUORINE RADIOISOTOPES; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES; TOMOGRAPHY, X-RAY COMPUTED;

EID: 79959820744     PISSN: 08853177     EISSN: 15364828     Source Type: Journal    
DOI: 10.1097/MPA.0b013e31821b5bf7     Document Type: Review

References (28)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin. 2009;59:225-249.
2. Tang S, Huang G, Liu J, et al. Usefulness of (18)F-FDG PET, combined FDG-PET/CT and EUS in diagnosing primary pancreatic carcinoma: A meta-analysis. Eur J Radiol. 2009 [Epub ahead of print].
3. Klapman JB, Chang KJ, Lee JG, et al. Negative predictive value of endoscopic ultrasound in a large series of patients with a clinical suspicion of pancreatic cancer. Am J Gastroenterol. 2005;100: 2658-2661.
4. Farma JM, Santillan AA, Melis M, et al. PET/CT fusion scan enhances CT staging in patients with pancreatic neoplasms. Ann Surg Oncol. 2008;15:2465-2471.
5. Higashi T, Saga T, Nakamoto Y, et al. Diagnosis of pancreatic cancer using fluorine-18 fluorodeoxyglucose positron emission tomography (FDG PET)Vusefulness and limitations in "clinical reality." Ann Nucl Med. 2003;17:261-279. (Pubitemid 37012038)
6. Zimny M, Bares R, Fass J, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography in the differential diagnosis of pancreatic carcinoma: A report of 106 cases. Eur J Nucl Med. 1997;24:678-682. (Pubitemid 27299751)
7. Rose DM, Delbeke D, Beauchamp RD, et al. 18Fluorodeoxyglucose-positron emission tomography in the management of patients with suspected pancreatic cancer. Ann Surg. 1999;229:729-737; discussion 737-738.
8. Imdahl A, Nitzsche E, Krautmann F, et al. Evaluation of positron emission tomography with 2-[18F]fluoro-2-deoxy-D-glucose for the differentiation of chronic pancreatitis and pancreatic cancer. Br J Surg. 1999;86:194-199. (Pubitemid 29090183)
9. Nakamoto Y, Higashi T, Sakahara H, et al. Delayed (18)F-fluoro-2-deoxy-D- glucose positron emission tomography scan for differentiation between malignant and benign lesions in the pancreas. Cancer. 2000;89:2547-2554. (Pubitemid 32011597)
10. Sendler A, Avril N, Helmberger H, et al. Preoperative evaluation of pancreatic masses with positron emission tomography using 18F- fluorodeoxyglucose: Diagnostic limitations. World J Surg. 2000;24:1121-1129.
11. Kasperk RK, Riesener KP, Wilms K, et al. Limited value of positron emission tomography in treatment of pancreatic cancer: Surgeon's view. World J Surg. 2001;25:1134-1139. (Pubitemid 32845824)
12. Nakamoto Y, Saga T, Higashi T, et al. Optimal scan time for evaluating pancreatic disease with positron emission tomography using F- 18Yfluorodeoxyglucose. Ann Nucl Med. 2003;17:421-426. (Pubitemid 37071269)
13. Buerkle A, Weber WA. Imaging of tumor glucose utilization with positron emission tomography. Cancer Metastasis Rev. 2008;27: 545-554.
14. Saif MW, Cornfeld D, Modarresifar H, et al. 18F-FDG positron emission tomography CT (FDG PET-CT) in the management of pancreatic cancer: Initial experience in 12 patients. J Gastrointestin Liver Dis. 2008;17:173-178. (Pubitemid 351930763)
15. Pessin JE, Bell GI. Mammalian facilitative glucose transporter family: Structure and molecular regulation. Annu Rev Physiol. 1992;54:911-930.
16. Higashi T, Saga T, Nakamoto Y, et al. Relationship between retention index in dual-phase (18)F-FDG PET, and hexokinase-II and glucose transporter-1 expression in pancreatic cancer. J Nucl Med. 2002;43: 173-180. (Pubitemid 34151039)
17. Reske SN, Grillenberger KG, Glatting G, et al. Overexpression of glucose transporter 1 and increased FDG uptake in pancreatic carcinoma. J Nucl Med. 1997;38:1344-1348.
18. Kawamura T, Kusakabe T, Sugino T, et al. Expression of glucose transporter-1 in human gastric carcinoma: Association with tumor aggressiveness, metastasis, and patient survival. Cancer. 2001;92:634-641. (Pubitemid 32735200)
19. Younes M, Brown RW, Mody DR, et al. GLUT1 expression in human breast carcinoma: Correlation with known prognostic markers. Anticancer Res. 1995;15:2895-2898. (Pubitemid 26095119)
20. Wahl RL, Henry CA, Ethier SP. Serum glucose: Effects on tumor and normal tissue accumulation of 2-[F-18]-fluoro-2-deoxy-D-glucose in rodents with mammary carcinoma. Radiology. 1992;183:643-647.
21. Lindholm P, Minn H, Leskinen-Kallio S, et al. Influence of the blood glucose concentration on FDG uptake in cancerVa PET study. J Nucl Med. 1993;34:1-6. (Pubitemid 23014212)
22. Ho CL, Dehdashti F, Griffeth LK, et al. FDG-PET evaluation of indeterminate pancreatic masses. J Comput Assist Tomogr. 1996;20:363-369. (Pubitemid 26142285)
23. Friess H, Langhans J, Ebert M, et al. Diagnosis of pancreatic cancer by 2[18F]-fluoro-2-deoxy-D-glucose positron emission tomography. Gut. 1995;36:771-777.
24. Bares R, Klever P, Hauptmann S, et al. F-18 fluorodeoxyglucose PET in vivo evaluation of pancreatic glucose metabolism for detection of pancreatic cancer. Radiology. 1994;192:79-86. (Pubitemid 24191522)
25. Strobel K, Heinrich S, Bhure U, et al. Contrast-enhanced 18F-FDG PET/CT: 1-stop-shop imaging for assessing the resectability of pancreatic cancer. J Nucl Med. 2008;49:1408-1413.
26. Sperti C, Pasquali C, Fiore V, et al. Clinical usefulness of 18-fluorodeoxyglucose positron emission tomography in the management of patients with nonpancreatic periampullary neoplasms. Am J Surg. 2006;191:743-748. (Pubitemid 43729402)
27. Sperti C, Bissoli S, Pasquali C, et al. 18-fluorodeoxyglucose positron emission tomography enhances computed tomography diagnosis of malignant intraductal papillary mucinous neoplasms of the pancreas. Ann Surg. 2007;246:932-937; discussion 937-939. (Pubitemid 350179174)
28. Baiocchi GL, Portolani N, Bertagna F, et al. Possible additional value of 18FDG-PET in managing pancreas intraductal papillary mucinous neoplasms: Preliminary results. J Exp Clin Cancer Res. 2008;27:10.